로딩 중…
지수 로딩 중…
ARS Pharmaceuticals, Inc.
SPRY· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$5.46+6.43%
2026-08-03
Financials
Valuation Metrics
ARS Pharmaceuticals, Inc.'s Market Cap is $542M. At end of 2025 it was $1.15B. Ranked #2789 of 3,111 in US market (top 90%), #1212 of 1,445 on NASDAQ (top 84%), #225 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 84%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $542M | US#2,789/3,111 Sec#225/269 |
| Revenue | $99M | US#2,788/3,111 Sec#126/269 |
| Net Income | $-198M | US—/3,111 Sec—/269 |
| Total Assets | $288M | US#2,917/3,111 Sec#219/269 |
| Net Assets | $61M | US#2,929/3,111 Sec#239/269 |
| Value | ||
| P/B | 8.84x | US#2,526/3,111 Sec#195/269 |
| P/S | 5.48x | US#2,297/3,111 Sec#82/269 |
| FCF Yield | -32.33% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROA | -68.84% | US#3,029/3,111 Sec#250/269 |
| Op. Margin | -204.49% | US#2,867/3,111 Sec#139/269 |
| Revenue Growth | 184.47% | US#77/3,111 Sec#23/269 |
| Earnings Growth | -2241.76% | US#2,387/3,111 Sec#96/269 |
| Financial Health | ||
| Debt Ratio | 369.06% | US#2,257/3,111 Sec#227/269 |
| Total Debt | $97M | US#2,427/3,111 Sec#121/269 |
| FCF | $-175M | US#2,718/3,111 Sec#206/269 |
| Cash | $24M | US#2,833/3,111 Sec#259/269 |
| Current Ratio | 4.94x | US#476/3,111 Sec#146/269 |
| Performance | ||
| 1Y Return | -68.22% | US#3,084/3,111 Sec#263/269 |
| 1M Return | -36.21% | US#3,061/3,111 Sec#262/269 |
| From 52W High | -69.67% | US#3,021/3,111 Sec#256/269 |
| 1Y MDD | -71.47% | US#2,943/3,111 Sec#247/269 |
| Trading | ||
| Volume | 1,965,876 shares | US#822/3,111 Sec#67/269 |
| Trading Value | $10M | US#2,245/3,111 Sec#180/269 |
| Per Share | ||
| EPS | $-1.74 | US—/3,111 Sec—/269 |
| BPS | $1.16 | US#2,605/3,111 Sec#197/269 |